Institutional implementation of clinical tumor profiling on an unselected cancer population

Sholl et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69ffc5f4da5c1eb07f2d88e0 — DOI: https://doi.org/10.1172/jci.insight.87062

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Detection of FLT3 Internal Tandem Duplication in Targeted, Short-Read-Length, Next-Generation Sequencing Data· 2012 · 138 citations
2. Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers· 2010 · 637 citations
3. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease· 1999 · 2,789 citations
4. Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches· 2015 · 270 citations
5. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials· 2015 · 428 citations